There are 490 papers on acute myocardial infarction in aging research: 19 trials and 396 observational studies in people, 13 in animals, 1 in cells, 41 reviews.
490 papers study it374 more mention it156 findings
148 new papers in 30 daysSee all 864 papers on acute myocardial infarction
“Statistically significant risk reduction was evident within 2–3 years [AMI: HR = 0.475, 95% confidence interval (CI) = 0.403–0.559;”
- Human trial19
- Humans396
- Animals13
- Cells1
- In silico9
Interventions
11GLP-1 receptor agonists
no changein humans3downin humans1HR 1.033
4 studies
GLP-1 receptor agonists
no changein humans3downin humans1HR 1.033
GLP-1 receptor agonists were not clearly linked with acute myocardial infarction in humans.
“acute myocardial infarction and incident heart failure with preserved ejection fraction did not differ significantly between cohorts”
Humansin adults with obesity and CRP 3-10 mg/L; active comparator metformin, orlistat or phentermineup to 3,650 daysn = 50,009
One drug class linked to fewer events in obesity with inflammation
The American journal of cardiology
GLP-1 receptor agonists were not clearly linked with acute myocardial infarction in humans (propensity-score matched cohort; 1-, 3- and 5-year follow-up).
“No significant differences were noted in AMI or CVA at 1-, 3-, and 5-years of follow-up.”
Humanspropensity-score matched cohort; 1-, 3- and 5-year follow-up1, 3 and 5 years
AHA Scientific Sessions 2025 abstract
GLP-1 receptor agonists were not clearly linked with acute myocardial infarction in humans (propensity-matched cohort; GLP-1RA started within 14 days after TAVI) (HR 1.033).
“No differences were observed in AMI (HR 1.033 [95% CI, 0.750-1.423]; p=0.844)”
Humanspropensity-matched cohort; GLP-1RA started within 14 days after TAVI1 yearn = 930
AHA Scientific Sessions 2025 abstract
GLP-1 receptor agonists are linked with lower acute myocardial infarction in humans (patients with T2DM and ESRD compared with matched non-users) (1.74% vs. 3.83%, OR 0.445, CI 0.297-0.667).
“as well as AMI (1.74% vs. 3.83%, OR 0.445, CI 0.297-0.667, p < 0.0001).”
Humanspatients with T2DM and ESRD compared with matched non-usersat least 6 months of therapyn = 2,009
ENDO 2025 abstract
SGLT2 inhibitors
no changein humans2RR 0.85–1.044
2 studies
SGLT2 inhibitors
no changein humans2RR 0.85–1.044
SGLT2 inhibitors were not clearly linked with acute myocardial infarction in humans (heart failure patients after TAVR, propensity score-matched cohort) (14.4% vs. 13.8%; RR 1.044 (95% CI 0.800-1.363)).
“Acute MI (14.4% vs. 13.8%; RR=1.044, 95% CI: 0.800-1.363, p=0.752)”
Humansheart failure patients after TAVR, propensity score-matched cohortn = 660
ESC Congress 2026 abstract
SGLT2 inhibitors were not clearly linked with acute myocardial infarction in patients receiving immune checkpoint inhibitors, after propensity score matching (RR 0.85, 95% CI 0.592-1.212).
“The risk of AMI (RR 0.85, 95% CI: 0.592-1.212, p-value 0.3625) and myocarditis (RR 1.001, 95% CI: 0.417-2.401, p-value 0.998) was similar between both groups.”
Humansin patients receiving immune checkpoint inhibitors, after propensity score matchingn = 2,862
AHA Scientific Sessions 2025 abstract
Inclisiran
no changein humans1HR 1.33
1 study
Inclisiran
no changein humans1HR 1.33
Inclisiran was not clearly linked with acute myocardial infarction in humans (8.2% vs 7.6%; HR 1.33, 95% CI 0.76–2.33; p=0.32).
“Inclisiran use was not significantly associated with acute myocardial infarction (8.2% vs 7.6%; HR, 1.33; 95% CI, 0.76 - 2.33; p=0.32)”
HumansMASLD and elevated cardiovascular risk; receiving statin and ezetimibe therapy; compared with no inclisiran3 yearsn = 317
AHA Scientific Sessions 2026 abstract
Semaglutide
no changein humans1RR 1.15
1 study
Semaglutide
no changein humans1RR 1.15
Semaglutide was not clearly linked with acute myocardial infarction in humans (3.6% vs. 3.1%; RR 1.15, 95% CI 0.69-1.93).
“No significant differences were observed in stroke or acute MI.”
HumansAtrial fibrillation with obesity or diabetes following catheter ablation; compared with tirzepatide3 years65% males
ESC Congress 2026 abstract
Tirzepatide
no changein humans1
1 study
Tirzepatide
no changein humans1
Tirzepatide was not clearly linked with acute myocardial infarction in humans (healthcare professional reports only) (ROR 0.45 [0.19-1.08]).
“no disproportionate reporting was detected for acute myocardial infarction (ROR 0.45 [0.19-1.08])”
Humanshealthcare professional reports only
Frontiers in pharmacology
Occupational noise
no changein humans1OR 1.008
1 study
Occupational noise
no changein humans1OR 1.008
Occupational noise was not clearly linked with acute myocardial infarction in humans (OR 1.008, 95% CI 0.998-1.018).
“acute myocardial infarction (P = .112; OR: 1.008; 95% CI: 0.998-1.018)”
Humans
Medicine
Poverty
no changein humans1HR 1.1
1 study
Poverty
no changein humans1HR 1.1
Poverty was not clearly linked with acute myocardial infarction in humans (cardiovascular risk factors) (HR 1.10, 95% CI 0.93 to 1.31).
“the association remained significant among women (HR 1.30, 95% CI 1.01 to 1.68), but not among men (HR 1.10, 95% CI 0.93 to 1.31).”
Humanscardiovascular risk factorsmalesn = 53,564
BMJ open
Physical activity
no changein humans1HR 0.95
1 study
Physical activity
no changein humans1HR 0.95
Physical activity was not clearly linked with acute myocardial infarction in humans (HR 0.95, 95% CI 0.72-1.25).
“There was no association between high-volume PA (>3000 MET-minutes per week) and risk for acute myocardial infarction (HR, 0.95 [95% CI, 0.72-1.25]).”
Humans>3000 MET-minutes per week20.5 yearsn = 26,724
Circulation
Ambient temperature
no changein humans1RR 0.999
1 study
Ambient temperature
no changein humans1RR 0.999
Ambient temperature was not clearly linked with acute myocardial infarction in humans (when it is 26°C) (RR 0.999 (95% CI 0.986, 1.012)).
“become increasing again when it is 26°C although not significantly (Risk ratio = 0.999 (95% CI 0.986, 1.012)”
Humanswhen it is 26°C
PloS one
Dutasteride
no changein humans1HR 0.94
1 study
Dutasteride
no changein humans1HR 0.94
Dutasteride was not clearly linked with acute myocardial infarction in humans (relative to finasteride) (HR 0.94, 95% CI 0.82-1.08).
“Similarly, we found no difference in the risk of acute myocardial infarction (HR 0.94, 95% CI 0.82-1.08) or stroke (HR 1.03, 95% CI 0.88-1.20).”
Humansrelative to finasteridemales
The Cardiovascular Safety of Dutasteride
The Journal of urology
All 11Fewer
Effects
2Inflammation
upin humans1
1 study
Inflammation
upin humans1
Acute myocardial infarction is linked with higher inflammation in humans (compared with older healthy controls).
“a significantly greater proportion of intermediate and non-classical CD80+ monocytes suggested a shift to a pro-inflammatory phenotype”
Humanscompared with older healthy controlsblood monocytesn = 21
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals
Aging
Classical CD163+CD80+ monocytes
downin humans1
1 study
Classical CD163+CD80+ monocytes
downin humans1
Acute myocardial infarction is linked with lower classical CD163+CD80+ monocytes in humans (compared with older healthy controls).
“The AMI patients showed a significantly decreased proportion of CD163+CD80+ and an increased proportion of CD163+ and CD163−CD80− cells among classical monocytes, opposite trends to those observed in healthy aging”
Humanscompared with older healthy controlsblood monocytesn = 21
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals
Aging
Upstream
5FI-LAB
no changein humans1HR 0.995
1 study
FI-LAB
no changein humans1HR 0.995
FI-LAB was not clearly linked with acute myocardial infarction in humans (patients with acute coronary syndrome undergoing percutaneous coronary intervention) (HR 0.995; 95% CI 0.854-1.160).
“but not with recurrent AMI (HR 0.995; 95% CI 0.854-1.160).”
Humanspatients with acute coronary syndrome undergoing percutaneous coronary intervention
European journal of cardiovascular nursing
Cholesterol uptake capacity
no changein humans1
1 study
Cholesterol uptake capacity
no changein humans1
Cholesterol uptake capacity was not clearly linked with acute myocardial infarction in humans (1.11 ± 0.45 vs. 1.16 ± 0.55, p = 0.6).
“non-significantly lower in the non-AMI vs. AMI group (1.11 ± 0.45 vs. 1.16 ± 0.55; p = 0.6)”
Humansserum
Journal of diabetes and metabolic disorders
HbA1c variability
no changein humans1HR 0.88
1 study
HbA1c variability
no changein humans1HR 0.88
HbA1c variability was not clearly linked with acute myocardial infarction in humans (type 2 diabetes) (HR = 0.88, 95% CI: 0.51-1.52).
“No significant associations were observed between HbA1c variability and AMI (HR = 0.88, 95% CI: 0.51-1.52)”
Humanstype 2 diabetesn = 18,293
Diabetes, obesity & metabolism
Inflammation
mediatesin humans1
1 study
Inflammation
mediatesin humans1
Inflammation is linked with acute myocardial infarction in humans (mediating CVH-AMI relationship) (1.57-8.62 %).
“Inflammatory/metabolic biomarkers mediated 1.57-8.62 % of the CVH-AMI relationship.”
Humansmediating CVH-AMI relationshipn = 122,914
American journal of preventive cardiology
Female sex
no changein humans1HR 1.02
1 study
Female sex
no changein humans1HR 1.02
female sex was not clearly linked with acute myocardial infarction in propensity-matched heart failure patients with cardiac amyloidosis on SGLT2 inhibitors (HR 1.02; 95% CI, 0.73–1.44).
“acute myocardial infarction (HR 1.02; 95% CI, 0.73–1.44)”
Humansin propensity-matched heart failure patients with cardiac amyloidosis on SGLT2 inhibitors3 yearsn = 466
AHA Scientific Sessions 2025 abstract
Associations
115SGLT2 inhibitors
downin humans6upin humans1HR 0.53–0.76
7 studies
SGLT2 inhibitors
downin humans6upin humans1HR 0.53–0.76
SGLT2 inhibitors are associated with acute myocardial infarction in humans (OR 0.64, 95% CI 0.53–0.77).
“and acute myocardial infarction (OR 0.64; 95% CI 0.53-0.77).”
HumansPatients with diabetes and bioprosthetic heart valves; propensity-score-matched comparison with non-usersApproximately 2.8±1.8 years
SGLT2 Inhibitor Use and Bioprosthetic Valve Re-Intervention in Patients with Diabetes
AHA Scientific Sessions 2026 abstract
SGLT2 inhibitors are associated with acute myocardial infarction in humans (RR 0.685, 95% CI 0.534–0.878; Kaplan-Meier analysis not statistically significant).
“Risk analysis showed lower rates of STEMI/acute MI (RR 0.685, 95% CI 0.534-0.878)”
HumansDialysis-dependent end-stage renal disease and HFrEF; risk analysis, with nonsignificant Kaplan-Meier analysisn = 998
SGLT2 Inhibitor Use in ESRD and HFrEF: A Retrospective Outcomes Analysis
AHA Scientific Sessions 2026 abstract
SGLT2 inhibitors are associated with acute myocardial infarction in humans (HR 0.76, 95% CI 0.57-0.99).
“AMI was significantly less at 5 years (HR 0.76; 95% CI 0.57-0.99; p=0.045)”
Humanscancer therapy-related HFrEF; SGLT2 inhibitor-based GDMT versus GDMT without SGLT2 inhibitors5 years
AHA Scientific Sessions 2026 abstract
SGLT2 inhibitors are associated with acute myocardial infarction in humans (moderate-to-severe plaque psoriasis receiving biologic therapy) (HR 0.601; 95% CI 0.426–0.849).
“SGLT2 inhibitor use was associated with a significantly lower incidence of acute myocardial infarction (HR, 0.601; 95%CI, 0.426-0.849)”
Humansmoderate-to-severe plaque psoriasis receiving biologic therapy
Actas dermo-sifiliograficas
SGLT2 inhibitors are linked with a lower risk of acute myocardial infarction in adults with Fabry disease, propensity-matched TriNetX cohort (HR 0.53; 95% CI 0.30-0.90).
“with reduced myocardial infarction risk (HR 0.53; 95% CI 0.30-0.90)”
Humansin adults with Fabry disease, propensity-matched TriNetX cohort5 yearsn = 732
Diabetes, obesity & metabolism
SGLT2 inhibitors are linked with a higher risk of acute myocardial infarction in humans (propensity-matched adults aged 80 years or older with chronic kidney disease).
“Acute myocardial infarction and acute heart failure were increased in the SGLT2i group.”
Humanspropensity-matched adults aged 80 years or older with chronic kidney diseasetwo yearsn = 10,076
medRxivPreprint
SGLT2 inhibitors are associated with acute myocardial infarction in humans (HR 0.64; 95% CI 0.56-0.72).
“SGLT2 inhibitor use was associated with fewer heart failure hospitalizations (HR 0.78; 95% CI 0.72-0.85) and acute myocardial infarctions (HR 0.64; 95% CI 0.56-0.72).”
Reviewstage 5 chronic kidney disease; association was no longer significant in treatment-initiation cohortsn = 57,156
medRxivPreprint
GLP-1 receptor agonists
downin humans4HR 0.63–1.234
4 studies
GLP-1 receptor agonists
downin humans4HR 0.63–1.234
GLP-1 receptor agonists are linked with a lower risk of acute myocardial infarction in humans (Type 2 diabetes and cancer; compared with DPP-4 inhibitors) (142 vs 212 events; HR 0.72, 95% CI 0.58–0.89).
“GLP-1 RA was associated with lower risk of MI (142 vs 212 events; HR 0.72, 95% CI 0.58-0.89)”
HumansType 2 diabetes and cancer; compared with DPP-4 inhibitors2 years51% males
AHA Scientific Sessions 2026 abstract
GLP-1 receptor agonists are linked with a lower risk of acute myocardial infarction in humans (HR 1.234, 95% CI 1.192–1.276 (SGLT2i versus GLP-1RA)).
“GLP-1RA therapy was associated with lower risk of acute myocardial infarction (HR 1.234, 95% CI 1.192–1.276; p<0.001)”
HumansObesity and type 2 diabetes mellitus; compared with SGLT2 inhibitors; reported HR uses SGLT2i versus GLP-1RA30 days through 5 years
AHA Scientific Sessions 2026 abstract
GLP-1 receptor agonists are associated with acute myocardial infarction in humans (Morbid obesity; users compared with propensity score-matched non-users) (HR 0.69, 95% CI 0.63–0.77).
“Overall, GLP-1 RA therapy was associated with lower risks of SCD, VT/VF, AMI, and all-cause mortality”
HumansMorbid obesity; users compared with propensity score-matched non-users5 years
Obesity drugs linked to lower sudden cardiac death risk
AHA Scientific Sessions 2026 abstract
GLP-1 receptor agonists are linked with a lower risk of acute myocardial infarction in humans (HR 0.63 (95% CI 0.54–0.73)).
“AMI (HR 0.63, 95% CI 0.54–0.73, p < 0.001)”
Humansin adults with HFpEF, type 2 diabetes and obesity, compared with standard of care without GLP-1 RAs3 yearsn = 5,474
AHA Scientific Sessions 2025 abstract
Tirzepatide
downin humans3HR 0.21–0.71
3 studies
Tirzepatide
downin humans3HR 0.21–0.71
Tirzepatide is associated with acute myocardial infarction in humans (PCOS and T2DM receiving metformin; propensity-matched comparison with no tirzepatide) (1.2% vs 7.5%; HR 0.21, 95% CI 0.03–0.35).
“acute myocardial infarction (1.2% vs 7.5%; HR, 0.21; 95% CI, 0.03 - 0.35; p<0.01)”
HumansPCOS and T2DM receiving metformin; propensity-matched comparison with no tirzepatide5 yearsfemalesn = 4,345
AHA Scientific Sessions 2026 abstract
Tirzepatide is associated with acute myocardial infarction in humans (elevated lipoprotein(a)) (HR 0.71; 95% CI, 0.52-0.98).
“tirzepatide use was associated with a lower hazard of MACE (HR 0.72; 95% CI, 0.58-0.89), AMI (HR 0.71; 95% CI, 0.52-0.98)”
Humanselevated lipoprotein(a)2 years
Tirzepatide Use and Major Adverse Cardiovascular Events Among Patients with Elevated Lipoprotein(a)
AHA Scientific Sessions 2026 abstract
Tirzepatide is linked with a lower risk of acute myocardial infarction in humans (propensity-matched comparison with GLP-1RAs in adults with T2DM and ischemic heart disease) (HR 0.59, 95% CI 0.38-0.91).
“acute myocardial infarction (HR: 0.59, 95% CI: 0.38-0.91)”
Humanspropensity-matched comparison with GLP-1RAs in adults with T2DM and ischemic heart disease1-year follow-up
JACC. Advances
In-hospital mortality
upin humans3OR 2.79
3 studies
In-hospital mortality
upin humans3OR 2.79
Acute myocardial infarction is associated with in-hospital mortality in humans (hospitalized with RSV-associated ARIs) (mOR 3.05, p = 0.005).
“and acute myocardial infarction (3.05, p = 0.005)”
Humanshospitalized with RSV-associated ARIs
Influenza and other respiratory viruses
Acute myocardial infarction is associated with in-hospital mortality in humans (OR 2.79; 95% CI 1.86–4.20).
“the strongest risk factors for in-hospital death for patients with a RRS call were advanced malignancy (OR 3.95; 95%CI 2.16-7.21) and new myocardial infarction (OR 2.79; 95%CI 1.86-4.20).”
HumansPatients receiving Rapid Response System attendances; adjusted for all investigated clinical indicatorsn = 328
Resuscitation
Acute myocardial infarction predicts in-hospital mortality in humans (Acute myocardial infarction less than 7 days before coronary artery bypass grafting).
“On multivariate logistic regression non sinus rhythm and acute myocardial infarction less than 7 days before surgery were independent predictors of in-hospital mortality.”
HumansAcute myocardial infarction less than 7 days before coronary artery bypass graftingIn-hospitaln = 182
Elective and urgent coronary surgery in octogenarians
Revista portuguesa de cirurgia cardio-toracica e vascular : orgao oficial da Sociedade Portuguesa de Cirurgia Cardio-Toracica e Vascular
Fine particulate matter
upin humans3
3 studies
Fine particulate matter
upin humans3
Fine particulate matter is associated with acute myocardial infarction in humans.
“Each 10-μg/m3 increase in lag-2 PM2.5 was significantly associated with an increased risk of AMI.”
HumansEach 10-μg/m3 increase in PM2.5 exposure2-day lagn = 270,091
European heart journal
Fine particulate matter is linked with a higher risk of acute myocardial infarction in humans (cumulative exposure Q4 vs Q1, fully adjusted) (IRR 1.24 [95% CI 1.18,1.31]).
“The most pronounced association was observed for PM2.5 with IRRs of 1.08 [95% CI 1.04,1.13], 1.14 [95% CI 1.09,1.20] and 1.24 [95% CI 1.18,1.31] in Q2–Q4”
Humanscumulative exposure Q4 vs Q1, fully adjustedn = 903,415
International archives of occupational and environmental health
Fine particulate matter is linked with a higher risk of acute myocardial infarction in humans (adjusted for individual risk factors).
“the Hazard Ratio (HR) for AMI and Ischemic Heart Disease (IHD) was 1.031 [0.95 CI = 1.005, 1.057]”
Humansadjusted for individual risk factors10 μg/m3 increase15 yearsn = 3,081
Environmental health : a global access science source
Smoking
upin humans2OR 3.51
2 studies
Smoking
upin humans2OR 3.51
Smoking is associated with acute myocardial infarction in humans (Prediagnostic smoking trajectories) (OR 3.51).
“The strongest associations were observed for acute myocardial infarction (OR 3.51) and cerebral infarction (OR 2.46).”
HumansPrediagnostic smoking trajectories
International journal of public health
Smoking raises the risk of acute myocardial infarction in humans.
“smoking remains the most consistent risk factor”
Review
Acute myocardial infarction in young adults: Changes in risk profile over the last decades
International Health Sciences Review
Statins
downin humans1upin humans1HR 0.805–5.34
2 studies
Statins
downin humans1upin humans1HR 0.805–5.34
Statins are linked with a lower risk of acute myocardial infarction in humans (without prior cardiovascular disease) (HR 0.805, 95% CI 0.731-0.887).
“In the fully adjusted Cox model, baseline statin exposure was associated with a lower risk of incident AMI (HR, 0.805; 95% CI, 0.731-0.887).”
Humanswithout prior cardiovascular diseasemedian follow-up of 5 yearsn = 174,014
medRxivPreprint
Statins are linked with a higher risk of acute myocardial infarction in humans (incident ESRD requiring permanent dialysis) (1.51% vs. 0.30%, HR 5.34 (95% CI 3.40-8.39)).
“acute myocardial infarction (1.51% vs. 0.30%, HR: 5.34, 95% CI: 3.40-8.39) compared to the nonstatin group (n = 1709).”
Humansincident ESRD requiring permanent dialysis> 90 days in the first year after initiation of dialysis
Journal of clinical medicine
Air pollution
upin humans2
2 studies
Air pollution
upin humans2
Air pollution is linked with a higher risk of acute myocardial infarction in humans.
“Our main analyses showed a clear exposure-response relationship between cumulative exposure to each of the air pollutants and incident AMI.”
Humansn = 903,415
International archives of occupational and environmental health
Air pollution raises the risk of acute myocardial infarction in humans.
“new emerging risk factors like air pollution (micro- and nanoplastics), periodontitis, acute stress, energy drinks, misuse of recreational drugs may increase risk and influence treatment, and outcomes of AMI in this young population.”
Review
Young hearts at risk: Unveiling novel factors in myocardial infarction susceptibility and prevention
Journal of family medicine and primary care
Mortality
upin humans2HR 4.631
2 studies
Mortality
upin humans2HR 4.631
Acute myocardial infarction is linked with a higher risk of mortality in humans (elderly patients with intertrochanteric fractures) (HR 4.631, 95% CI 2.190-9.795).
“AMI (HR 4.631, 95% CI 2.190-9.795, P < 0.001)”
Humanselderly patients with intertrochanteric fractures
Clinical interventions in aging
Acute myocardial infarction is linked with a higher risk of mortality in humans after femoral neck fracture surgery (OR 1.317, 95% CI 1.240-1.400).
“acute myocardial infarction (AMI) (OR 1.317; 95% CI, 1.240-1.400)”
Humansafter femoral neck fracture surgery1 year
Hip international : the journal of clinical and experimental research on hip pathology and therapy
Low serum magnesium
upin humans1HR 1.77
1 study
Low serum magnesium
upin humans1HR 1.77
Low serum magnesium is associated with acute myocardial infarction in humans (Prior metabolic and bariatric surgery; low versus normal magnesium) (HR 1.77, 95% CI 1.24–2.53).
“Low magnesium was associated with higher mortality (HR 1.34, 95% CI 1.06–1.69) and higher hazards of acute myocardial infarction (HR 1.77, 95% CI 1.24–2.53)”
HumansPrior metabolic and bariatric surgery; low versus normal magnesiumDay 90 through 3 years
Frontiers in nutrition
All 115Fewer
Trial sponsors
Shanghai Hutchison Pharmaceuticals
Company1 trialPhase 49,588 people
Company1 trialPhase 41,116 people
Company1 trialPhase 325,000 people
Company1 trialPhase 310,000 people
Novartis Pharmaceuticals Corporation
Company1 trialPhase 35,669 people
Company1 trialPhase 34,017 people
Shenzhen Salubris Pharmaceuticals
Company1 trialPhase 3380 people
Company1 trialPhase 3332 people
Funding
9 grants since 2016National Heart, Lung, and Blood Institute$4.8MAmerican Heart Association$307KJapan Society for the Promotion of Science¥3.4M
Frailty and Resiliency in Older Adults with Acute Myocardial Infarction
National Heart, Lung, and Blood InstituteCleveland Clinic Lerner Com-cwru$183K2020–2027
National Heart, Lung, and Blood InstituteYale University$729K2023–2028
Natural Science Foundation of Hunan ProvinceUniversity of South China2025
Influenza Infection and acute myocardial infarction
Nederlandse Organisatie voor Wetenschappelijk OnderzoekUniversitair Medisch Centrum Utrecht2020–2025
Multifunctional Antibody Therapy for Acute Myocardial Infarction
National Heart, Lung, and Blood InstituteTranstarget$225K2018–2020
National Heart, Lung, and Blood InstituteRevidia Therapeutics$730K2017–2021
Opening the Black Box into Functional Decline Among Older Adults with Acute Myocardial Infarction
American Heart AssociationYale University$154K2017–2019
Japan Society for the Promotion of ScienceWakayama Medical University¥3.4M2017–2020
American Heart AssociationNew York University$153K2016–2017